A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

Inclusion Criteria: * Has relapsed or refractory (rr) DLBCL; has progressed after at least 2 lines of prior therapy; and has progressed after auto- stem cell transplant (SCT) or are auto-SCT ineligible. Must have received prior multiagent regimen that includes an alkylating agent. anthracycline, and anti-CD20 (cluster of differentiation 20) monoclonal antibody. * Has histologically confirmed diagnosis of DLBCL. * Has radiographically measurable DLBCL per the Lugano Response Criteria. * Should either be post- chimeric antigen receptor T cell therapy (CAR-T) failure or ineligible for CAR-T (for any reason). * Life expectancy of at least 3 months. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before time of enrollment. * Has adequate organ function. Exclusion Criteria: * Has received a diagnosis of Primary mediastinal B-cell lymphoma (PMBCL). * Has undergone solid organ transplant at any time. * Has a history of any clinically significant cardiovascular conditions within 6 months of screening or serious cardiac arrhythmia requiring medication. * Has known history of liver cirrhosis. * Has pericardial effusion or clinically significant pleural effusion. * Has ongoing Grade \>1 peripheral neuropathy. * Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. * Transformed DLBCL from indolent lymphoma. * In participants with prior allo-SCT, a…